UBS Maintains Buy on Chimera Investment, Raises Price Target to $16
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
UBS analyst Douglas Harter maintains Chimera Investment (NYSE:CIM) with a Buy and raises the price target from $15 to $16.
UBS analyst Douglas Harter maintains Chimera Investment (NYSE:CIM) with a Buy and raises the price target from $15 to $16.